Financhill
Back

Axsome Therapeutics Quote, Financials, Valuation and Earnings

Buy
54

AXSM
Axsome Therapeutics

Last Price:
75.29
Seasonality Move:
-2.14%

7 Day Trial

ALL ACCESS PASS

$ 7

Axsome Therapeutics Price Quote

$75.29
+0.10 (+1.5%)
(Updated: May 25, 2024 at 6:06 AM ET)

Axsome Therapeutics Key Stats

Buy
54
Axsome Therapeutics (AXSM) is a Buy

Day range:
$74.19 - $75.41
52-week range:
$55.02 - $98.40
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
13.89
P/B ratio:
24.79%

Volume:
377.2K
Avg. volume:
558.4K
1-year change:
9.4%
Market cap:
$3.6B
Revenue:
$270.6M
EPS:
$-6.38

How Much Does Axsome Therapeutics Make?

Is Axsome Therapeutics Growing As A Company?

  • What Is Axsome Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.21%
  • What Is Axsome Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Axsome Therapeutics Stock Price Performance

What Is Axsome Therapeutics 52-Week High & Low?

Axsome Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Axsome Therapeutics?

Is Axsome Therapeutics Cash Flow Positive?

  • What Is AXSM Cash Flow From Operations?
    Cash flow from operations (TTM) is -$192.7M
  • What Is Axsome Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $278.3M
  • What Is Axsome Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$609K

Axsome Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    AXSM return on invested capital is -79.94%
  • What Is Axsome Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -54.17%
  • What Is AXSM Return On Equity?
    ROE is a measure of profitability and is -148.91%

Axsome Therapeutics Earnings Date & Stock Price

Axsome Therapeutics Competitors

  • Who Are Axsome Therapeutics's Competitors?
    Below is a list of companies who compete with Axsome Therapeutics or are related in some way:
    • ADMA Biologics Inc (ADMA)
    • Catalyst Pharmaceuticals Inc (CPRX)
    • Krystal Biotech Inc (KRYS)
    • Vertex Pharmaceuticals Inc (VRTX)
    • Vistagen Therapeutics Inc (VTGN)

Axsome Therapeutics Dividend Yield

Data Unavailable

Axsome Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -17.65%
Revenue: -20.7% 2.95%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 123.56
Upside from Last Price: 64.33%

Major Shareholders

  • How many AXSM shares are owned by institutional investors?
    52.4M AXSM shares are owned by institutional investors
  • How many AXSM shares are owned by insiders?
    214.3K AXSM shares are owned by insiders